Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-cash Items: 2015-2025

Historic Non-cash Items for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to $156.6 million.

  • Iovance Biotherapeutics' Non-cash Items rose 950.85% to $156.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.6 million, marking a year-over-year increase of 950.85%. This contributed to the annual value of $14.1 million for FY2024, which is 16.26% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Non-cash Items stood at $156.6 million, which was up 964.95% from $14.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Non-cash Items high stood at $156.6 million for Q3 2025, and its period low was $6.2 million during Q2 2024.
  • Moreover, its 3-year median value for Non-cash Items was $14.1 million (2024), whereas its average is $28.5 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Non-cash Items slumped by 66.22% in 2024 and then surged by 950.85% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Non-cash Items stood at $12.2 million in 2023, then increased by 16.26% to $14.1 million in 2024, then surged by 950.85% to $156.6 million in 2025.
  • Its Non-cash Items stands at $156.6 million for Q3 2025, versus $14.7 million for Q2 2025 and $14.6 million for Q1 2025.